Sugi Predict

Sugi Predict / Compounds / SCHEMBL401370

SCHEMBL401370

SCHEMBL401370

CN(C)CC(=O)N1CCC(C(c2ccc3ccc(-c4ccccc4)nc3c2)c2ncc3c(N)nccn23)CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ TNK2 Q07912 1/20 0.43
▸ IGF1R P08069 13/20 0.42
▸ CYP3A4 P08684 9/20 0.42
▸ KDR P35968 7/20 0.39
▸ PIK3CA P42336 6/20 0.39
▸ MAPK3 P27361 2/20 0.39
▸ MAPK1 P28482 2/20 0.39
▸ INSR P06213 2/20 0.39
▸ MTOR P42345 2/20 0.39
▸ RIPK2 O43353 1/20 0.39
▸ ROCK2 O75116 1/20 0.39
▸ LATS1 O95835 1/20 0.39
▸ LCK P06239 1/20 0.39
▸ LYN P07948 1/20 0.39
▸ RET P07949 1/20 0.39
▸ ABCB1 P08183 1/20 0.39
▸ MET P08581 1/20 0.39
▸ FGFR1 P11362 1/20 0.39
▸ INSRR P14616 1/20 0.39
▸ FECH P22830 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL396481 0.91 IGF1R (0.42) TNK2IGF1RCYP3A4KDRMAPK3
SCHEMBL402712 0.91 IGF1R (0.41) IGF1RCYP3A4KDRPIK3CAMAPK3
SCHEMBL398345 0.90 IGF1R (0.43) IGF1RCYP3A4KDRPIK3CAMAPK3
SCHEMBL400429 0.86 IGF1R (0.40) IGF1RCYP3A4KDRMAPK3MAPK1
SCHEMBL398837 0.77 GRIN2B (0.38) CYP3A4
SCHEMBL401580 0.75 TNK2 (0.71) TNK2IGF1RCYP3A4KDRMAPK3
SCHEMBL401368 0.73 IGF1R (0.59) TNK2IGF1RCYP3A4KDRMAPK3
SCHEMBL400836 0.69 IGF1R (0.33) IGF1RCYP3A4KDRMAPK3MAPK1
SCHEMBL14031798 0.67 TNK2 (0.56) TNK2IGF1RCYP3A4KDRMAPK3
SCHEMBL14031990 0.66 IGF1R (0.46) TNK2IGF1RCYP3A4KDRPIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168968-B1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS LLC (US) 2017-08-23 — — EP disclosed
US-8653268-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2014-02-18 — — US disclosed
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2013-07-25 — — US disclosed
US-8367826-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2013-02-05 — — US disclosed
US-20120077979-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI Pharmaceuticals, LLC 2012-03-29 — — US disclosed
US-8101613-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, LLC (US) 2012-01-24 — — US disclosed
EP-2308879-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2011-04-13 — — EP disclosed
EP-2305682-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2011-04-06 — — EP disclosed
US-7820662-B2 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2010-10-26 — — US disclosed
EP-2168968-A1 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI Pharmaceuticals, Inc. (US) 2010-03-31 — — EP disclosed
US-20090325928-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-12-31 — — US disclosed
EP-1740591-B1 6,6-BICYCLIC RING SUBSTITUTED HETEROBICYCLIC PROTEIN KINASE INHIBITORS OSI PHARM INC (US) 2009-06-17 — — EP disclosed
US-7534797-B2 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors OSI PHARMACEUTICALS, INC. (US) 2009-05-19 — — US disclosed
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors OSI PHARMACEUTICALS, INC. 2009-05-07 — — US disclosed
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors ACERTA PHARMA B.V. (NL) 2006-10-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120077979-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 TNK2 405/4885IGF1R 1/4885CYP3A4 1815/4885
US-20090325928-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 TNK2 405/4885IGF1R 1/4885CYP3A4 1815/4885
US-20130190496-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 TNK2 405/4885IGF1R 1/4885CYP3A4 1815/4885
US-20090118499-A1 6,6-Bicyclic Ring Substituted Heterobicyclic Protein Kinase Inhibitors IGF1R, MAP2K7, BRCA1 TNK2 405/4885IGF1R 1/4885CYP3A4 1815/4885
US-20060235031-A1 6,6-Bicyclic ring substituted heterobicyclic protein kinase inhibitors IGF1R, MAP2K7, BRCA1 TNK2 405/4885IGF1R 1/4885CYP3A4 1815/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.